Global Eye Melanoma Market is anticipated to register with a CAGR of 7.8% during the forecast period
The Global Eye Melanoma market is anticipated to register a CAGR of 7.8%. Melanoma is a cancer that affects melanin-producing cells. Eye melanoma, also known as ocular melanoma, is a cancer that originates in the sclera, retina, and uvea, the three layers of the eye. Early symptoms of eye melanoma include floaters, a growing dark spot on the iris, a change in the shape of the pupil in the center of the eye, poor or blurry vision in one eye, and loss of peripheral vision, but later symptoms include floaters, a growing dark spot on the iris, a change in the shape of the pupil in the center of the eye, poor or blurry vision in one eye, and loss of peripheral vision.
The report " Global Eye Melanoma Market, By Site (Uvea, Sclera and Retina), By Diagnosis (Imaging, Biopsy and Eye exam), By Treatment (Surgery, Radiation therapy and Laser treatment), By End-User (Hospital & Clinics and Academic Institutes) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030”
PV-10, a small molecule oncolytic immunotherapy, gained Orphan Drug designation from the US FDA in February 2019 for the treatment of eye melanoma, including any melanoma illness affecting the eye and orbit.
The US FDA granted Aura Biosciences, Inc Fast Track designation for AU-011, an experimental novel molecule for the treatment of eye melanoma, in March 2017. This is a different type of treatment that works by using a light-activated viral nanoparticle to specifically kill cancer cells.
To know the upcoming trends and insights prevalent in this market, click the link below: